Clinical study of Aripiprazole combined with Haloperidol Decanoate in the treatment of residual schizophrenia
CAI San-jiang1 TAN Yuan-hua1 JI Ying1 ZHANG Guang-ping1 ZHANG Bo-cheng
1. Department of Psychiatry, Xinyu Hospital of Traditional Chinese Medicine, Jiangxi Province, Xinyu 338025, China;
2. Department of Internal Medicine, Xinyu Hospital of Traditional Chinese Medicine, Jiangxi Province, Xinyu 338025,China
Abstract：Objective To investigate the clinical effect of Aripiprazole combined with Haloperidol Decanoate in the treatment of residual schizophrenia. Methods A total of 50 patients with residual schizophrenia who were treated in our hospital from January 2019 to January 2020 were included in this study. According to the random number table control method, they were divided into two groups, 25 cases in each group. The control group received Aripiprazole Tablets. The patients in the study group received Aripiprazole Tablets combined with Haloperidol Decanoate injection. The changes of PANSS and TESS were compared before and after treatment in the two groups.Results The positive symptom score,negative symptom score, general psychopharmacology score and total score of the two groups at 2, 4, 6 weeks of treatment were lower than those of the same group before treatment, the differences were statistically significant (P＜0.05); the positive symptom score, negative symptom score, general psychopharmacology score and total score of the study group at 2,4, 6 weeks of treatment were lower than those of the control group at the same time, the differences were statistically significant (P＜0.05); the TESS scores of the two groups increased gradually at 2, 4, 6 weeks of treatment, the differences were statistically significant(P＜0.05); there were no significant differences in TESS scores between the two groups(P＞0.05). Conclusion The combination of Aripiprazole and Haloperidol Decanoate can improve the therapeutic effect of residual schizophrenia, and will not significantly increase adverse reactions, which is worthy of clinical recommendation.
蔡三江；谭远华；计颖；张广平；张博成. 阿立哌唑联合癸酸氟哌啶醇治疗残留型精神分裂症的临床研究[J]. 中国当代医药, 2020, 27(28): 68-70.
CAI San-jiang； TAN Yuan-hua； JI Ying；ZHANG Guang-ping；ZHANG Bo-cheng. Clinical study of Aripiprazole combined with Haloperidol Decanoate in the treatment of residual schizophrenia. 中国当代医药, 2020, 27(28): 68-70.
Leucht S，Barabássy A，Laszlovszky I，et al.Linking PANSS negative symptom scores with the Clinical Global Impressions Scale：understanding negative symptom scores in schizophrenia[J].Neuropsychopharmacology，2019，44（9）：1589-1596.
[7]
Beck S，Patsalis T，Busch A，et al.Long-term results of the reverse Total Evolutive Shoulder System （TESS）[J].Arch Orthop Trauma Surg，2019，139（8）：1039-1044.
京公网安备 11010502046607号